Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil
β Scribed by Edward C. S. Lai; T. K. Choi; C. H. Cheng; Francis P. T. Mok; S. T. Fan; Eliza S. Y. Tan; John Wong
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 314 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Transcatheter arterial chemoembolization (tace) has been contra-indicated for the treatment of patients with hepatocellular carcinoma (hcc) and main portal vein (mpv) obstruction because of the potential risk of hepatic insufficiency resulting from ischemia after tace. the current co
## BACKGROUND. Although physical and emotional function after the diagnosis of breast carcinoma have been described in clinic populations, to the authors' knowledge no previous study has measured change from the preillness level of functional health status in community-dwelling women. ## METHODS.
## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel